The choice of a compressor for the aerosolisation of tobramycin (TOBI ( R)) with the PARI LC PLUS ( R) reusable nebuliser

Author： de Boer A.H.   Hagedoorn P.   Frijlink H.W.  

Publisher： Elsevier

ISSN： 0378-5173

Source： International Journal of Pharmaceutics, Vol.268, Iss.1, 2003-12, pp. : 59-69

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhaled Tobramycin (TOBI®): A Review of its Use in the Management of Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis

By Cheer S.M.   Waugh J.   Noble S.  

Drugs, Vol. 63, Iss. 22, 2003-01 ,pp. : 2501-2520

Adis International

Access to resources Recommend Favorite

Is the R and R* dichotomy real?

By Tuc S.  

Trends in Pharmacological Sciences, Vol. 18, Iss. 11, 1997-11 ,pp. : 414-416

Elsevier

Access to resources Recommend Favorite

Rituximab plus methotrexate-based chemotherapy (R-MPV) and whole-brain radiotherapy (WBRT) is promising for primary CNS lymphoma

By  

Inpharma, Vol. 1, Iss. 1613, 2007-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies

By  

Current Pharmaceutical Design, Vol. 14, Iss. 21, 2008-07 ,pp. : 2085-2099

Bentham Science Publishers

Access to resources Recommend Favorite

Is pharmaceutical R

By Schmid E.F.   Smith D.A.  

Drug Discovery Today, Vol. 9, Iss. 1, 2004-01 ,pp. : 18-26

Elsevier

Access to resources Recommend Favorite